Bristol Myers lung cancer trial shows 11.1-month PFS
Bristol Myers Squibb (NYSE:BMY) and SystImmune reported positive Phase 3 PANKU-Lung01 results showing that izalontamab brengitecan extended median progression-free survival to 11.1 months in previously treated EGFR-mutated non-small cell lung cancer.











